Variant of Concern 202012/01 Technical briefing 4 This briefing provides an update on the briefing of 8 January 2021 Nomenclature of variants in the UK SARS-CoV-2 variants if considered to have concerning epidemiological, immunological or pathogenic properties are raised for formal investigation. At this point they are designated Variant Under Investigation (VUI) with a year, […]
The world is in midst of the COVID-19 pandemic.The SARS-CoV-2 lineage B.1.1.28 has been evolving in Brazil since February 2020. A new lineage, named P.1 (B.1.1.28.1), contains convergent mutations in the spike (S) protein, including several receptor binding domain (spike RBD) mutations E484K, K417T, and N501Y. Spike Mutation in SARS-COV-2 (2019nCOV) Brazilian variant P.1 lineage […]
Variant of Concern 202012/01Technical briefing 3 Nomenclature of variants in the UK SARS-CoV-2 variants if considered to have concerning epidemiological, immunological or pathogenic properties are raised for formal investigation. At this point they are designated Variant Under Investigation (VUI) with a year, month, and number. Following risk assessment with the relevant expert committee, they may […]
The world is in midst of the COVID-19 pandemic. Recently a new SARS-CoV-2 (2019nCOV) lineage (501Y.V2,, B.1.351), characterised by eight lineage-defining mutations in the spike protein (excluding D614G mutation), including three at important residues in the receptor-binding domain (K417N, E484K and N501Y), represents increased transmissibility. This lineage emerged in South Africa and spread rapidly, becoming […]
1. GeneMedi information and products collection of SARS-COV-2 (2019nCOV) UK B.1.1.7 lineage and South Africa 501Y.V2 lineage and Brazilian P.1 lineage(B.1.1.28.1) Background Reading:Information and products collection of SARS-COV-2 (2019nCOV) UK B.1.1.7 lineageInformation and products collection of SARS-COV-2 (2019nCOV) South Africa 501Y.V2 lineageinformation and products collection of SARS-COV-2 (2019nCOV) Brazilian P.1 lineage (B.1.1.28.1) GeneMedi pseudotyped virus […]
PSV validated Data Poster Download Protocol Download BACKGROUND Challenge of COVID-19 vaccine discovery & development: to meet accumulated mutating of SARS-CoV-2 and a long-term viral genome transcrption COVID-19 (Coronavirus Disease 2019) is novel viral pneumonia caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2, also called 2019nCoV). The world is in midst of the COVID-19 […]
About COVID-19 pandemic, Coronavirus (Coronavirus) and genome of SARS-CoV-2 (2019nCoV) COVID-19 pandemic is caused by 2019nCoV (SARS-CoV-2, a novel coronavirus) infection.The 2019-nCoV genome was annotated to possess 14 ORFs encoding 27 proteins1. Figure. Schematic representative of genome structure and encoded gene of SARS-CoV-2 (2019nCoV)1 Table.Genome Annotation of 2019-nCoV1 Protein length(aa) orf1a 266-13483 4405 […]
About SARS-CoV-2 (2019nCoV, novel Coronavirus)Non-structure protein (Nsp1-Nsp16) 2019nCoV contains 16 Non-structure protein (Nsp1-Nsp16) that may be drugable targets for antiviral compounds discovery against COVID-191. Non-structure protein(NSP)information of SARS-CoV-2 (2019nCoV)1 nsp1 1 180 180 (leader protein) nsp2 181 818 638 nsp3 819 2763 1945 (Papain-Like proteinase, PLpro) nsp4 2764 3263 500 nsp5 […]
About SARS-CoV-2 (2019nCoV, novel Coronavirus) Nucleocapsid protein (Coronavirus N protein) 1. SARS-CoV-2 (2019nCoV) N protein: Coronavirus N protein is required for coronavirus RNA synthesis, and has RNA chaperone activity that may be involved in template switch. Nucleocapsid protein is a most abundant protein of coronavirus. N protein packages the positive strand viral genome RNA into a helical […]
About SARS-CoV-2 (2019nCoV, novel Coronavirus) membrane protein (Coronavirus M protein) 1. SARS-CoV-2 (2019nCoV) M protein: Coronavirus M protein is believed to define the shape of the viral envelope,which contains three transmembrane domains. It has a small N-terminal glycosylated ectodomain and a much larger C-terminal endodomain that extends 6–8 nm into the viral particle. M protein usualy exists […]
